Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238,273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.
Friedes BD, DiNofia AM, Iannone E, Li Y, Rheingold SR, Barz Leahy A, Wray L, Callahan C, Baniewicz D, Vernau L, Getz KD, Aplenc R, Maude SL, Grupp SA, Myers RM. Friedes BD, et al. Among authors: li y. Blood Adv. 2024 Nov 20:bloodadvances.2024014518. doi: 10.1182/bloodadvances.2024014518. Online ahead of print. Blood Adv. 2024. PMID: 39565957 No abstract available.
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
Myers RM, Devine K, Li Y, Lawrence S, Leahy AB, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim GB, Kulikovskaya I, Gonzalez VE, Fraietta JA, DiNofia AM, Hunger SP, Rheingold SR, Aplenc R, June CH, Grupp SA, Wray L, Maude SL. Myers RM, et al. Among authors: li y. Blood Adv. 2024 May 14;8(9):2182-2192. doi: 10.1182/bloodadvances.2024012885. Blood Adv. 2024. PMID: 38386999 Free PMC article.
Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment.
Cahen VC, Li Y, Getz KD, Elgarten CW, DiNofia AM, Wilkes JJ, Winestone LE, Huang YV, Miller TP, Gramatges MM, Rabin KR, Fisher BT, Aplenc R, Seif AE. Cahen VC, et al. Among authors: li y. Pediatr Blood Cancer. 2021 Sep;68(9):e28315. doi: 10.1002/pbc.28315. Epub 2020 May 11. Pediatr Blood Cancer. 2021. PMID: 32391940
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL. Myers RM, et al. Among authors: li y. J Clin Oncol. 2021 Sep 20;39(27):3044-3055. doi: 10.1200/JCO.20.03458. Epub 2021 Jun 22. J Clin Oncol. 2021. PMID: 34156874 Free PMC article.
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, Dolan JG, Callahan C, Baniewicz D, Devine K, Wray L, Aplenc R, June CH, Grupp SA, Rheingold SR, Maude SL. Leahy AB, et al. Among authors: li y. Lancet Haematol. 2021 Oct;8(10):e711-e722. doi: 10.1016/S2352-3026(21)00238-6. Lancet Haematol. 2021. PMID: 34560014 Free PMC article. Clinical Trial.
238,273 results
You have reached the last available page of results. Please see the User Guide for more information.